Trial Profile
A Phase 1, Randomized, Single-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety and Tolerability of a Single Dose of Intravenous ALN-TTR01 in Patients With TTR Amyloidosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ALN TTR01 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 29 Apr 2014 New trial record